Myanmar Country Fact Sheet

Epidemic

*Blue – representative sample; **Red – non-representative sample; MSM – men who have sex with men and PWID – people who inject drugs

Policies

Hepatitis B vaccine
- Birth dose of Hep B vaccine - YES
- Hep B immunization included in routine infant immunization schedule - YES
- Vaccination for HCWs - NO
- Vaccination for high risk groups (key populations) - NA

Blood & Injection safety
- Donated blood screened for Hep B & Hep C - YES
- Use of RUP syringes - NA
- Needle and syringe distribution program for PWID - YES

Hepatitis testing
- Is there official guidance for diagnosing HBV - YES
- Is there official guidance for diagnosing HCV - YES

Mortality

Access to medicines

Availability of medicines for Hep B treatment: Tenofvir, Entecavir
Annual cost for Hep B treatment: $36

Availability of DAAs for Hep C treatment: Sofosbuvir, Daclatasvir, Velpatasvir
Annual cost for Hep C treatment: $182 (12 weeks)

Health sector response

National Plan for viral hepatitis
Coverage of 3-dose Hep B vaccine schedule: 89% (2017)
Coverage of Hep B vaccine for newborns: 1% (2017)
Needles and syringes distributed per PWID in the last one year: 223

Source: Country survey

Abbreviations: HCWs- health care workers, PLHIV – people living with HIV, RUP – re-use prevention

Source:: Country survey

Estimate of facilities offering serological testing (HBsAg) for HBV - >300
Estimate of facilities offering nucleic acid testing (NAT) for HBV - 1
Estimate of facilities offering serological testing (Anti-HCV) for HCV - >300
Estimate of facilities offering nucleic acid testing (NAT) for HCV - 6

Source: WHO GHE, 2016